Roivant

Sketch of lungs
Biotech

Roivant’s midstage asset fails to show benefit in lung disease

Given the results, Kinevant is terminating development of the candidate—dubbed namilumab—as a potential sarcoidosis treatment.
Gabrielle Masson Dec 3, 2024 10:32am
Graphic of a pair of scissors cutting a 100 bill

Pfizer closes R&D unit that spawned $7.1B anti-TL1A med

Apr 17, 2024 7:00am
Graphic of a dart right on a bullseye sun breaking through the clouds in the background

Roivant's inflammatory med is back on track with ph. 2 NIU data

Apr 2, 2024 10:37am
light idea burst ruin destroy lightning shot

JPM24: Roivant CEO has ‘pangs of regret’ for letting Telavant go

Jan 12, 2024 10:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Immunovant posts midphase FcRn data in Graves’, plots next steps

Dec 21, 2023 7:00am
Roche building

Roche pays $7B to challenge Merck for bowel disease market

Oct 23, 2023 6:00am